Orchid Pharma rises on incorporating Wholly Owned Subsidiary
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
Orchid Pharma is currently trading at Rs. 284.95, up by 0.55 points or 0.19% from its previous closing of Rs. 284.40 on the BSE.
The scrip opened at Rs. 285.35 and has touched a high and low of Rs. 286.80 and Rs. 283.00 respectively.
The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 2680.00 on 05-Apr-2021 and a 52 week low of Rs. 260.20 on 25-Feb-2022.
Last one week high and low of the scrip stood at Rs. 290.00 and Rs. 275.00 respectively. The current market cap of the company is Rs. 1163.06 crore.
The promoters holding in the company stood at 90.00%, while Institutions and Non-Institutions held 5.17% and 4.84% respectively.
Orchid Pharma has incorporated a Wholly Owned Subsidiary in India namely ‘Orchid Bio-Pharma’ on March 24, 2022, with the object to venture into the business of manufacturing Bio tech chemicals and intermediates. The incorporation of the wholly owned subsidiary will leverage the growth opportunities in the evolving pharma space.
Orchid Pharma, established as an export-oriented unit (EOU), is a vertically integrated company spanning the entire pharmaceutical value chain from discovery to delivery with established credentials in research, manufacturing and marketing.
